A new publication from the EUTOPS team describes an epigenetic signature in a cervico-vaginal sample, the WID-EC test, that detects and predicts the risk of future womb cancer up to 4 years before diagnosis. This publication completes the set of four publications demonstrating that DNA methylation signature assessment using methylation array analysis in cervical screening samples is able to detect and likely predict the risk for all four major women’s cancers: breast, ovarian, womb and cervical cancer. New studies to validate the risk predictive nature of the test are planned.

Find a video outlining the principle of the test below, or read the research: